Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, Cheikh J, Briones J, Gülbas Z, Hamladji RM, Elverdi T, Blaise D, Martínez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A. Bazarbachi A, et al. Among authors: elverdi t. Leukemia. 2022 Jun;36(6):1646-1653. doi: 10.1038/s41375-022-01563-8. Epub 2022 Apr 12. Leukemia. 2022. PMID: 35414657
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B. Salihoglu A, et al. Among authors: elverdi t. Ann Hematol. 2015 Mar;94(3):415-20. doi: 10.1007/s00277-014-2215-9. Epub 2014 Sep 18. Ann Hematol. 2015. PMID: 25231929 Free PMC article.
Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN, Elverdi T, Kaynar L, Ayyildiz O, Yonal Hindilerden I, Goksoy HS, Izmir Guner S, Gunes AK, Sonmez M, Kurt Yuksel M, Civriz Bozdag S, Ozkurt ZN, Toptas T, Dogu MH, Salim O, Saydam G, Yavasoglu I, Ayli M, Ozet G, Albayrak M, Birtas Atesoglu E, Toprak SK, Yildirim R, Mehtap O, Kalayoglu Besisik S, Nalcaci M, Altuntas F, Ferhanoglu B. Akay OM, et al. Among authors: elverdi t. Hematol Oncol. 2021 Oct;39(4):498-505. doi: 10.1002/hon.2897. Epub 2021 Jun 25. Hematol Oncol. 2021. PMID: 34171130
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko-Jarosinska J, Tanase A, Akhtar S, Ben Othman T, Ma'koseh M, Afanasyev B, El-Cheikh J, Briones J, Gülbas Z, Hamladji RM, Elverdi T, Blaise D, Martínez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A. Bazarbachi A, et al. Among authors: elverdi t. Leukemia. 2022 Aug;36(8):2150. doi: 10.1038/s41375-022-01639-5. Leukemia. 2022. PMID: 35840758 No abstract available.
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Ferhanoglu B, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: elverdi t. Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18. Leuk Res. 2014. PMID: 24832371
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T, Ferhanoğlu B. Öztürk E, et al. Among authors: elverdi t. Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26294270 No abstract available.
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: elverdi t. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28847475
44 results